Terns Pharmaceuticals Inc
NASDAQ:TERN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
China Information Technology Development Ltd
HKEX:8178
|
HK |
|
Solaris Oilfield Infrastructure Inc
NYSE:SOI
|
US |
|
Ringer Hut Co Ltd
TSE:8200
|
JP |
|
Kirloskar Industries Ltd
NSE:KIRLOSIND
|
IN |
|
M
|
Mytilineos SA
SWB:MYH
|
GR |
|
Prozone Realty Ltd
NSE:PROZONER
|
IN |
|
Westgold Resources Ltd
ASX:WGX
|
AU |
|
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
|
IN |
|
Tokai Kisen Co Ltd
TSE:9173
|
JP |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (10.1), the stock would be worth $-10.78 (120% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -49.2 | $52.65 |
0%
|
| Industry Average | 10.1 | $-10.78 |
-120%
|
| Country Average | 14.4 | $-15.36 |
-129%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Terns Pharmaceuticals Inc
NASDAQ:TERN
|
5.9B USD | -49.2 | -61.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 28.7 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 17.2 | 26.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 16.8 | 30.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.5 | 19.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 12.6 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 10 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.3 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 7.7 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 7.2 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Terns Pharmaceuticals Inc
Glance View
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.
